产品名称：Carotuximab

中文名称：卡妥昔单抗

产品别称：Chimeric anti-CD105 antibody, TRC-105, DE-122

靶点：Endoglin/CD105 [Homo sapiens]

抗体亚型：IgG1 Kappa

分子量：145.5 kDa

克隆性：Monoclonal

来源：CHO Cells

体外实验：Carotuximab靶向主动脉内皮细胞上的CD105，通过抑制CD105的表达、配体结合和下游信号通路激活等方式，进而阻断了高胆固醇和高糖诱导的单核细胞跨内皮层迁移和转移。[1]

体内实验：与decitabine (DAC)联合用药，Carotuximab靶向CD105+ AML原细胞，增强了ROS活性，具有更持久的抗白血病效果

参考文献：1.Tripska K, Igreja Sá IC, Vasinova M, et al. Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells. Front Med (Lausanne). 2022;9:845918. Published 2022 Sep 7. doi:10.3389/fmed.2022.845918

                2.Baik J, Felices M, Yingst A, et al. Therapeutic effect of TRC105 and decitabine combination in AML xenografts. Heliyon. 2020;6(10):e05242. Published 2020 Oct 13. doi:10.1016/j.heliyon.2020.e05242

仅供科研使用